To the full analysis
Buyback calculator for Fennec Pharmaceuticals
Fennec Pharmaceuticals stock: key metrics
FENCFennec Pharmaceuticals had an operating margin of −14.2% and a return on invested capital (ROIC) of −10.3% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | no data | no data | no data |
| 2007 | no data | no data | no data |
| 2008 | no data | no data | no data |
| 2009 | no data | no data | no data |
| 2010 | no data | no data | no data |
| 2011 | no data | no data | no data |
| 2012 | no data | no data | no data |
| 2013 | no data | no data | no data |
| 2014 | no data | no data | no data |
| 2015 | no data | no data | no data |
| 2016 | no data | no data | no data |
| 2017 | no data | no data | no data |
| 2018 | no data | no data | no data |
| 2019 | no data | no data | no data |
| 2020 | 100.0% | −10,520.6% | −10,652.4% |
| 2021 | no data | no data | no data |
| 2022 | 94.4% | −1,481.3% | −1,544.9% |
| 2023 | 94.1% | −61.4% | −75.5% |
| 2024 | 93.3% | 5.2% | −0.9% |
| 2025 | 91.6% | −14.2% | −21.8% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −100.0% | no data | −100.0% |
| 2007 | −94.4% | −84.0% | −77.6% |
| 2008 | −100.0% | no data | −100.0% |
| 2009 | −100.0% | no data | −100.0% |
| 2010 | 158.9% | no data | −100.0% |
| 2011 | −100.0% | no data | 87.6% |
| 2012 | 104.2% | no data | −100.0% |
| 2013 | −100.0% | no data | 105.3% |
| 2014 | −100.0% | no data | −91.7% |
| 2015 | −100.0% | no data | −64.7% |
| 2016 | −78.1% | no data | −70.2% |
| 2017 | −26.3% | −36.2% | −24.8% |
| 2018 | −46.4% | −34.2% | −43.1% |
| 2019 | −100.0% | −63.4% | −92.4% |
| 2020 | −62.3% | −69.0% | −57.6% |
| 2021 | −100.0% | −54.6% | −77.4% |
| 2022 | 200.0% | −83.4% | −88.0% |
| 2023 | 138.1% | −49.5% | −59.7% |
| 2024 | 7.4% | 6.8% | −1.0% |
| 2025 | −27.8% | −10.3% | −13.9% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 10 Nov 2026, previously Weak
- Valuation signal Undervalued since 13 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.